News
CPRX
17.59
+1.27%
0.22
Catalyst sells Canadian rights to Duchenne drug to Kye Pharma
Healthcare Catalyst sells Canadian rights to Duchenne drug to Kye Pharma. U.S. FDA approved Agamree in October. Kye will assume full responsibility for obtaining Canadian approval for DMD drug. Catalyst will receive upfront payment, reimbursement and sales royalties.
Seeking Alpha · 2d ago
CATALYST PHARMACEUTICALS ENTERS INTO AN EXCLUSIVE LICENSE, SUPPLY AND COMMERCIALIZATION AGREEMENT WITH KYE PHARMACEUTICALS FOR AGAMREE® IN CANADA
Reuters · 2d ago
Weekly Report: what happened at CPRX last week (0715-0719)?
Weekly Report · 4d ago
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
Catalyst Pharmaceuticals, Inc. Will release its second quarter 2024 financial results after the market close on August 7, 2024. The company is a commercial-stage biopharmaceutical company focused on novel medicines for patients living with rare and difficult-to-treat diseases.
Barchart · 4d ago
These small-cap stocks score highest when screened for quality
MarketWatch · 07/17 15:57
Weekly Report: what happened at CPRX last week (0708-0712)?
Weekly Report · 07/15 10:23
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Catalyst Pharma (CPRX) and Eli Lilly & Co (LLY)
TipRanks · 07/10 13:10
Weekly Report: what happened at CPRX last week (0701-0705)?
Weekly Report · 07/08 10:23
Catalyst Pharmaceuticals: New Products In Proving Phase
Catalyst Pharmaceuticals, Inc. Has three approved products. The company has acquired FYCOMPA and AGAMREE in recent years. Its future intellectual property status beyond 2024 is deep in litigation. Catalyst's product portfolio has grown through acquisitions to three. The firm has a positive outlook for additional business development opportunities.
Seeking Alpha · 07/06 07:24
Weekly Report: what happened at CPRX last week (0624-0628)?
Weekly Report · 07/01 10:24
Catalyst Pharmaceuticals (NASDAQ:CPRX): A Growth-Oriented Value Investment Opportunity
TipRanks · 06/24 11:28
Weekly Report: what happened at CPRX last week (0617-0621)?
Weekly Report · 06/24 10:28
Weekly Report: what happened at CPRX last week (0610-0614)?
Weekly Report · 06/17 10:23
Catalyst Pharmaceuticals Inc <CPRX.OQ> expected to post earnings of 26 cents a share - Earnings Preview
Catalyst Pharmaceuticals Inc. Expected to post earnings of 26 cents a share. The company is expected to report a 12.4% increase in quarterly revenue to $111.96 million. The average analyst estimate is for earnings of 26 cents per share for the period ending June 30 2024.
Reuters · 06/14 13:02
Weekly Report: what happened at CPRX last week (0603-0607)?
Weekly Report · 06/10 10:24
Catalyst Pharmaceuticals Inc <CPRX.OQ> expected to post earnings of 26 cents a share - Earnings Preview
Catalyst Pharmaceuticals Inc expected to post earnings of 26 cents a share. The company is expected to report a 12.4% increase in quarterly revenue to $111.96 million. The average analyst estimate for the company is for earnings of 26 cents per share.
Reuters · 06/07 12:35
Catalyst Pharmaceuticals Price Target Maintained With a $29.00/Share by Oppenheimer
Dow Jones · 06/06 14:33
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Ventyx Biosciences (VTYX) and Catalyst Pharma (CPRX)
TipRanks · 06/06 11:50
Catalyst Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 06/05 22:15
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months. The biopharmaceutical company focuses on developing and commercializing therapies for rare diseases. The company has an average 12-month price target of $28.43. Catalyst Pharmaceuticals has a revenue growth rate of 15.4% over the past year.
Benzinga · 06/03 13:00
More
Webull provides a variety of real-time CPRX stock news. You can receive the latest news about Catalyst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.